Yes, GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide are FDA-approved treatments for type 2 diabetes. They lower blood sugar mainly by boosting glucose-dependent insulin release, lowering glucagon, and slowing digestion, effects that also tend to reduce appetite and support weight loss. Because that insulin boost is glucose-dependent, these drugs carry a relatively low risk of hypoglycemia on their own, but risk climbs when they're combined with insulin or sulfonylureas, so medication adjustments are a conversation for your clinician.
Key takeaways
- GLP-1 drugs were developed for type 2 diabetes; weight-loss uses came later and use different brand names and doses.
- They lower blood sugar through glucose-dependent insulin release, lower glucagon, and slowed digestion.
- Hypoglycemia risk from a GLP-1 alone is relatively low, but rises when combined with insulin or sulfonylureas.
- Diabetes approvals and weight-management approvals belong to different products, even when the active ingredient is the same.
Are GLP-1 drugs approved for diabetes?
Yes. GLP-1 receptor agonists were first approved for type 2 diabetes, and several remain core diabetes treatments today: semaglutide as Ozempic, dulaglutide as Trulicity, liraglutide as Victoza, and exenatide-based products. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is approved as Mounjaro for type 2 diabetes. It's worth noting that the weight-management versions of these molecules, Wegovy (semaglutide) and Zepbound (tirzepatide), are separate FDA-approved products for chronic weight management rather than diabetes, even though they share an active ingredient with their diabetes counterparts. Our medications overview maps out how the whole drug family fits together.
These drugs are typically used alongside diet and exercise, and often alongside other diabetes medications, rather than as a stand-alone first step for everyone. The right combination depends on your individual blood sugar goals, other health conditions, and how you tolerate the medication.
Because GLP-1 and dual GIP/GLP-1 medications for diabetes come in several molecules, several brand names, and several delivery formats, it's easy to get the diabetes and weight-management versions confused, especially since some products share an active ingredient with a differently branded weight-management counterpart. When you're discussing options with your clinician, it helps to be clear about which goal you're prioritizing, blood sugar control, weight loss, or both, since that shapes which specific product, dose, and monitoring plan makes sense for you.
How GLP-1 drugs lower blood sugar
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating. GLP-1 receptor agonist medications mimic and amplify that hormone's effects in a few connected ways:
- Glucose-dependent insulin release. They prompt the pancreas to release more insulin, but mainly when blood sugar is already elevated, which is part of why the hypoglycemia risk from the GLP-1 itself is comparatively low.
- Lower glucagon. They reduce the liver's release of glucagon, a hormone that normally raises blood sugar, helping prevent the liver from releasing extra glucose after meals.
- Slower gastric emptying. Food moves into the small intestine more gradually, which smooths out the post-meal blood sugar spike.
- Reduced appetite. Effects on appetite centers in the brain lower food intake, which is where the weight-loss benefit comes from, and weight loss itself further improves blood sugar control.
Tirzepatide adds a second mechanism on top of this, activity at the GIP receptor as well as the GLP-1 receptor, which appears to add to the blood-sugar and weight effects compared with a GLP-1 alone.
Because these mechanisms work together rather than in isolation, the overall effect on any individual's blood sugar can vary quite a bit based on how much insulin resistance they have, how much weight they lose, what else they eat, and which other medications they're taking. This is one reason clinicians monitor blood sugar closely in the weeks after starting or adjusting a GLP-1, rather than assuming a fixed, predictable drop for everyone. Regular blood sugar monitoring, and periodic A1c checks, help your care team see how your body is actually responding and adjust the plan accordingly.
| Use | Example products | Primary FDA-approved goal |
|---|---|---|
| Type 2 diabetes | Ozempic, Mounjaro, Trulicity, Victoza | Improve blood sugar (A1c) control, alongside diet and exercise |
| Chronic weight management | Wegovy, Zepbound, Saxenda | Weight loss and maintenance in eligible adults |
| Both indications, different products | Semaglutide and tirzepatide families | Same molecule, separate approvals, doses, and brand names for each use |
Do GLP-1 drugs cause low blood sugar?
Used alone, GLP-1 drugs have a relatively low risk of causing hypoglycemia, precisely because their insulin-boosting effect depends on blood sugar already being high. The risk changes when a GLP-1 is added to insulin or a sulfonylurea, medications that lower blood sugar regardless of the current level. In that situation, your clinician may reduce the dose of the insulin or sulfonylurea to keep the combined effect balanced. This is exactly the kind of adjustment you should not make on your own; if you notice symptoms of low blood sugar, shakiness, sweating, confusion, or unusual hunger, tell your prescriber rather than changing a dose yourself. Our side effects guide covers this alongside the other common reactions people notice.
Why weight loss comes with blood sugar control
Weight loss and improved blood sugar control tend to reinforce each other. As appetite drops and food intake decreases, many people with type 2 diabetes lose a meaningful amount of weight on a GLP-1, and that weight loss itself tends to improve insulin sensitivity, which further helps blood sugar control. This is part of why GLP-1 therapy is often discussed for its dual benefit in diabetes care, though the primary approved goal for diabetes-labeled products remains glycemic control rather than weight loss. Anyone specifically seeking a weight-management approval should discuss the weight-management-specific products with their clinician, see our weight loss overview for how those compare.
It's also worth setting expectations around pace. Blood sugar improvements can show up relatively early as the medication takes effect and appetite changes kick in, while meaningful weight loss tends to build more gradually over weeks and months as the dose is titrated upward. Your clinician will typically look at both trends together, along with any side effects, when deciding whether to continue increasing the dose, hold steady, or adjust other medications you're taking alongside the GLP-1.
Frequently asked questions
Are GLP-1 drugs used for diabetes?
Yes. Several GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide are FDA-approved specifically to improve blood sugar control in adults with type 2 diabetes, often alongside diet and exercise.
How do GLP-1 drugs lower blood sugar?
They mimic a natural gut hormone that prompts the pancreas to release more insulin when blood sugar is high, reduces the liver's release of glucagon, and slows gastric emptying, all of which help smooth out blood sugar swings after meals.
Do GLP-1 drugs cause hypoglycemia?
On their own, GLP-1 drugs carry a relatively low risk of hypoglycemia because their insulin-boosting effect is glucose-dependent. The risk rises when they are combined with insulin or sulfonylureas, so your clinician may need to adjust those other medications.
Which GLP-1 drugs are approved for type 2 diabetes?
Semaglutide (Ozempic), dulaglutide (Trulicity), liraglutide (Victoza), exenatide products, and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro) are FDA-approved for type 2 diabetes. Related products such as Wegovy and Zepbound are approved for weight management rather than diabetes.
Sources & further reading
- U.S. Food & Drug Administration, prescribing information for semaglutide, tirzepatide, dulaglutide, and liraglutide diabetes products.
- American Diabetes Association, Standards of Care guidance on incretin-based therapies for type 2 diabetes.